In any event, here is a bit of Samsung Bioepis version of the the release:
. . . .Under the agreement, Samsung Bioepis will be responsible for preclinical and clinical development, process development and manufacturing, clinical trials and registration. Merck will be responsible for commercialization. Samsung Bioepis will receive an upfront payment from Merck, product supply income and will be eligible for additional payments associated with pre-specified clinical and regulatory milestones. Further financial terms were not disclosed. . . .
Personally, I think they could have just txted it. More seriously, we will keep you posted. [This is the 3,000th post on this blog. Woot!]